- Home
- LRE vs ANTX Comparison
LRE vs ANTX Comparison
Compare LRE & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- ANTX
- Stock Information
- Founded
- LRE 2001
- ANTX 2017
- Country
- LRE Japan
- ANTX United States
- Employees
- LRE 70
- ANTX N/A
- Industry
- LRE
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- ANTX Health Care
- Exchange
- LRE Nasdaq
- ANTX Nasdaq
- Market Cap
- LRE 29.9M
- ANTX 31.9M
- IPO Year
- LRE 2023
- ANTX 2022
- Fundamental
- Price
- LRE $2.23
- ANTX $1.23
- Analyst Decision
- LRE
- ANTX Hold
- Analyst Count
- LRE 0
- ANTX 5
- Target Price
- LRE N/A
- ANTX $3.50
- AVG Volume (30 Days)
- LRE 44.1K
- ANTX 918.3K
- Earning Date
- LRE 01-01-0001
- ANTX 11-13-2024
- Dividend Yield
- LRE N/A
- ANTX N/A
- EPS Growth
- LRE N/A
- ANTX N/A
- EPS
- LRE 0.29
- ANTX N/A
- Revenue
- LRE $117,804,154.00
- ANTX N/A
- Revenue This Year
- LRE N/A
- ANTX N/A
- Revenue Next Year
- LRE N/A
- ANTX N/A
- P/E Ratio
- LRE $7.30
- ANTX N/A
- Revenue Growth
- LRE 8.82
- ANTX N/A
- 52 Week Low
- LRE $1.19
- ANTX $0.87
- 52 Week High
- LRE $13.76
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- LRE 58.84
- ANTX 65.23
- Support Level
- LRE $2.02
- ANTX $0.98
- Resistance Level
- LRE $2.29
- ANTX $1.04
- Average True Range (ATR)
- LRE 0.13
- ANTX 0.07
- MACD
- LRE -0.00
- ANTX 0.02
- Stochastic Oscillator
- LRE 67.35
- ANTX 52.58
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.